Feb 23 2010
Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG;
OTCQX: RHHBY), today announced that a Phase III study (AVAGAST) did not
meet its primary endpoint of showing Avastin® (bevacizumab)
plus Xeloda® (capecitabine) or 5-FU and cisplatin
chemotherapy extended the lives of people with inoperable or advanced
stomach (gastric) cancer, compared to chemotherapy alone. Adverse events
in the trial were consistent with those previously reported for Avastin
and no new safety signals have been observed to date. Data from the
study will be submitted for presentation at the 2010 American Society of
Clinical Oncology (ASCO) annual meeting, June 4 to 8, 2010.
“We are disappointed with these results because treatment options for
stomach cancer are limited. However, we look forward to sharing the data
with the medical community, including secondary endpoints”
“We are disappointed with these results because treatment options for
stomach cancer are limited. However, we look forward to sharing the data
with the medical community, including secondary endpoints,” said Hal
Barron, M.D., executive vice president, Global Development and chief
medical officer. “We are committed to developing medicines for people
with stomach cancer, including Herceptin and Xeloda.”
These findings do not impact Avastin’s approved uses or its development
program. Avastin is being studied worldwide in more than 450 clinical
trials for multiple types of cancer.
Source Genentech
How different types of bread impact cancer risk